Stay updated on AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial
Sign up to get notified when there's something new on the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page.

Latest updates to the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page
- Check3 days agoChange DetectedThe page now displays the clinical trial record for the completed AMG 820 and pembrolizumab study, with details on its design, eligibility, outcomes, locations, and data-sharing information.SummaryDifference66%

- Check10 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA sitewide NIH notice about terminology during the website transition appears, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check38 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check45 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the usual content and indicating restricted access to the study information. This prevents users from viewing trial details like eligibility, status, and results on this page.SummaryDifference0.5%

- Check52 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record. This suggests access to the study details is blocked.SummaryDifference19%

Stay in the know with updates to AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page.